Search the webpage

Category: Glaucoma

Optic nerve head remodeling is generally considered the earliest manifestation of the glaucomatous triad, resulting in the subsequent damage to the axons of the optic nerve and ultimately retinal ganglion cells death. Optic nerve head astrocytes (ONHAs) are the primary cell type in the optic nerve head, where they provide both structural and nutrient support to the optic nerve. Activation of ONHAs, also referred to reactive astrocytosis or astrogliosis, represents the underlying physiological mechanism of optic nerve head remodeling.

Targeting reactive astrocytosis (“glioprotection”) has recently gained a strong interest in the development of novel pharmaceutical strategies for glaucoma that can supplement IOP-lowering agents.

Experimentica Ltd. offers a validated and standardized screening method for glioprotective drug candidates using primary adult rat ONHAs.

SUMMARY

Species

Rats (Brown Norway)

In vitro insult

Oxidative stress (tert-butylhydroperoxide, tBHP)

Format

96-well plate, tBHP dose response, 8 replicates per concentration

Read-outs

Cell viability assays (e.g. MTT, lactate dehydrogenase)

Please contact us, if you would like to receive more information: info@experimentica.com

IMAGES

Representative examples from primary rat ONHAs

Validated culture of primary adult ONHAs. We use the validated cultures of primary rat adult ONHAs (Kaja et al., 2015) to screen glioprotective drug candidates. ONHAs express the astrocyte markers S100b, EAAT1 and GFAP.

Cell viability assays. Dose-response curve for tBHP using MTT and LDH assays and effect by the prototypic antioxidant Trolox, serving as positive control. Data are shown as mean ± s.e.m. from five separate plates and were analyzed using ANOVA (P < 0.001). # P < 0.01, $ P < 0.001 based on a Bonferroni post-hoc test compared to the control condition (0 mM tBHP).

SELECTED PUBLICATIONS

REFERENCES

  1. Kaja S et al. Plate reader-based cell viability assays for glioprotection using primary rat optic nerve head astrocytes. Experimental Eye Research 2015; 138: 159-166.

LATEST NEWS

Meet us at SMi’s Ophthalmic Drugs Conference 2019 in London, UK, 2019

News
We are pleased to be a part of the 3rd Annual Ophthalmic Drugs Conference and Focus Day, taking place on ... Read More

Experimentica Ltd. is a member of BioMelbourne Network

News
We are delighted to become a member of BioMelbourne Network together with other committed organisations engaged in biotechnology, medical technology, ... Read More

Let’s meet at Global Biotech VIP Week in Melbourne, 2019

News
Experimentica’s CEO Giedrius Kalesnykas attends Global Biotech VIP Week in Melbourne, Australia, sponsored by Global Victoria, and participates in AusBiotech ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!